Transgene Biotek gears up to launch its block-buster drugs - TrabiDHA (DHA) formulations

10 Oct 2012 Evaluate

Transgene Biotek is geared up to launch one of its block-buster drugs - TrabiDHA (DHA) formulations. With the successful development of TrabiDHA in both oil and powder forms, the company is now actively pursuing several formulations in the form of soft and hard capsules and into several other formulations to cater to the hugely expanding neutraceutical markets containing DHA, apart from catering to the demands from animal health care division too.

Transgene Biotek is the first Indian company to undertake the entire spectrum of vegetable DHA range from the production to the final formulations. DHA is essential for the proper functioning of brains as adults, and for the development of nervous system and visual abilities during the first 6 months of life. In addition, omega-3 fatty acids are part of a healthy diet that helps lower risk of heart disease.

Transgene Biotek, is a biotechnology company. It is involved in the development of several cutting edge technologies.

Transgene Biotek Share Price

7.07 0.14 (2.02%)
01-Nov-2024 18:59 View Price Chart
Peers
Company Name CMP
Apollo Hospital Ent. 7036.65
Max Healthcare Inst 1006.75
Narayana Hrudayalay 1249.35
Aster DM Healthcare 444.55
Global Health 1115.50
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.